Home > Healthcare > Medical Services > Inpatient and Outpatient Services > Basal Cell Carcinoma Treatment Market

Basal Cell Carcinoma Treatment Market Trends

Report ID: GMI10474
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Basal Cell Carcinoma Treatment Market Trends

The expansion of the market is significantly bolstered by heightened disease awareness initiatives. Public health campaigns and educational programs have effectively raised consumer awareness pertaining to the importance of skin protection, regular skin checks, and early intervention. This surge in awareness has translated into a notable increase in the number of individuals seeking medical advice and treatment for BCC, thereby driving the demand for advanced diagnostic and therapeutic solutions.

For instance, as per the American Academy of Dermatology (AAD) report, there has been 25% increase in free skin cancer screenings from 2010 to 2020, resulting in the early identification of numerous skin cancer cases including BCC. Similarly, a survey by the American Cancer Society indicated a 30% rise in public knowledge of skin cancer risks and preventive measures. This heightened awareness has led to more frequent dermatological consultations, thereby accelerating the growth of the BCC treatment market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The basal cell carcinoma treatment market accounted for USD 7.1 billion in 2023 and is expected to grow at 8.6% CAGR driven by increasing incidence of basal cell carcinoma, primarily due to heightened exposure to UV radiations.

The nodular segment in the basal cell carcinoma treatment market held 66.5% share in 2023 as it is easier to detect early compared to other skin cancer subtypes.

North America basal cell carcinoma treatment industry is expected to record at 8.3% CAGR to reach USD 5.6 billion by 2032, owing to increasing disease incidence among aging population demographics, coupled with heightened awareness of skin cancer risks.

Almirall, S.A, Bausch Health Companies Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., Genentech, Inc., Merck & Co., Inc., and Mylan N.V. among others